当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
药品名称
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
承诺描述
Conduct “A phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 [ADYNOVATE] following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A” [clinical study 261303] – ADULT COMPONENT ONLY.